Related Experiment Videos
[Biological markers in hepatocellular carcinoma]
1Laboratoire d'Anatomie et de Cytologie pathologiques et Clinique des maladies du foie, Rennes.
Annales De Biologie Clinique
|January 1, 1988
Summary
Improving liver cancer diagnosis requires reliable biomarkers. Alpha-feto-protein is a reference, but its accuracy can be enhanced with new methods for early detection.
Area of Science:
- Hepatology and oncology research.
- Biochemical marker analysis.
- Diagnostic test development.
Context:
- Primary liver cancer has poor prognosis and limited therapeutic options, especially in inter-tropical Africa and South-East Asia.
- Effective therapy is often limited to surgical excision, necessitating early detection.
- Current screening relies on biological markers, with alpha-feto-protein as the primary reference test.
Purpose:
- To explore the limitations of alpha-feto-protein as a diagnostic marker for primary liver cancer.
- To identify strategies for improving the diagnostic accuracy and score of alpha-feto-protein.
- To investigate alternative and complementary biomarkers for early liver cancer screening.
Summary:
- Alpha-feto-protein (AFP) is the current standard for liver cancer diagnosis but has moderate specificity and is often absent in early stages.
- Proposed improvements to AFP's diagnostic utility include using monoclonal antibodies, analyzing fucosylated AFP forms, and combining it with other markers.
- Other potential biomarkers investigated include alpha-L-fucosidase and decarboxy-prothrombin.
Impact:
- Enhanced diagnostic strategies could lead to earlier detection of primary liver cancer.
- Improved screening methods may improve patient prognosis and treatment outcomes.
- Further research into combined biomarker approaches can refine liver cancer diagnostics.